Personalized chemo combo aims to beat childhood hodgkin lymphoma
NCT ID NCT03755804
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 30 times
Summary
This study tests different chemotherapy combinations based on a child's risk level for Hodgkin lymphoma. Low- and intermediate-risk patients receive a standard drug mix, while high-risk patients get a newer combination including brentuximab vedotin. The goal is to improve response rates and reduce the need for radiation. The trial enrolls children and young adults up to age 25.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Lucile Packard Children's Hospital Stanford University
Palo Alto, California, 94304, United States
-
Maine Children's Cancer Program
Scarborough, Maine, 04074, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
St. Jude Affiliate Baton Rouge Clinic (Our Lady of the Lakes Regional Medical Center)
Baton Rouge, Louisiana, 70809, United States
-
St. Jude Affiliate Clinic at Novant Health Hemby Children's Hospital
Charlotte, North Carolina, 28204, United States
-
St. Jude Children's Research Hospital
Memphis, Tennessee, 38105, United States
-
St. Jude Midwest Affiliate - Peoria
Peoria, Illinois, 61637, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bendamustine, etoposide, doxorubicin, bleomycin, vincristine, vinblastine, prednisone, filgrastim, brentuximab vedotin, cyclophosphamide, dacarbazine
What this could lead to
If successful, this could lead to more effective, personalized chemotherapy regimens for children with Hodgkin lymphoma, potentially reducing the need for radiation and long-term side effects.
What could go wrong
This is a mid-stage (Phase 2) trial with a moderate number of participants. The treatments involve strong chemotherapy drugs with known risks like infection, organ damage, and secondary cancers. Results may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.